Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Clinical Trials
3.5k
Trial Phases
6 Phases
Drug Approvals
91
Drug Approvals
Duloxetine Hydrochloride Enteric Capsules
- Product Name
- 欣百达
- Approval Number
- 国药准字HJ20150284
- Approval Date
- Aug 6, 2024
Duloxetine Hydrochloride Enteric Capsules
- Product Name
- 欣百达
- Approval Number
- 国药准字HJ20150285
- Approval Date
- Aug 6, 2024
Duloxetine Hydrochloride Enteric Capsules
- Product Name
- 欣百达
- Approval Number
- 国药准字HJ20150287
- Approval Date
- Jun 27, 2024
Duloxetine Hydrochloride Enteric Capsules
- Product Name
- 欣百达
- Approval Number
- 国药准字HJ20150286
- Approval Date
- Jun 27, 2024
Duloxetine Hydrochloride Enteric Capsules
- Product Name
- 欣百达
- Approval Number
- H20150287
- Approval Date
- Jul 3, 2019
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3007 trials with phase data)• Click on a phase to view related trials
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- Interventions
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 920
- Registration Number
- NCT07174336
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Summit Cancer Care, PC, Savannah, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
- Conditions
- NauseaVomitingNeoplasmsDrug-Related Side Effects and Adverse Reactions
- Interventions
- Drug: PlaceboDrug: Standard of Care Antiemetic TherapiesDrug: Background Chemotherapy
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT07169851
- Locations
- 🇺🇸
Marin Cancer Care, Greenbrae, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
- Conditions
- Renal ImpairmentHealthyRenal InsufficiencyEnd Stage Renal Disease (ESRD)
- Interventions
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT07165015
- Locations
- 🇺🇸
Omega Research Orlando LLC, Orlando, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4500
- Registration Number
- NCT07165028
- Locations
- 🇺🇸
Spectrum Research Institute, Gilbert, Arizona, United States
🇺🇸Adobe Gastroenterology, Tucson, Arizona, United States
🇺🇸Del Sol Research Management, LLC, Tucson, Arizona, United States
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT07165002
- Locations
- 🇭🇺
Clinical Research Units Hungary, Kistarcsa, Hungary
🇳🇿New Zealand Clinical Research Auckland, Auckland, New Zealand
🇸🇰Summit Clinical Research, s.r.o. - Bratislava, Bratislava, Slovakia
- Prev
- 1
- 2
- 3
- 4
- 5
- 397
- Next
News
Dualitas Therapeutics Emerges from Stealth with $65M Series A to Advance Bispecific Antibody Pipeline
Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.
Lilly Commits $5 Billion to Virginia Manufacturing Facility for Bioconjugate and ADC Production
Eli Lilly announces plans to build a $5 billion manufacturing facility in Virginia's Goochland County, marking the company's first dedicated bioconjugate platform and monoclonal antibody production site.
Drug Hunter Secures Seed Investment to Expand Knowledge Platform for Pharmaceutical R&D
Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.
CatalYm Strengthens Leadership Team to Advance Visugromab Through Late-Stage Development
CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.
Takeda Appoints Former Eli Lilly Executive Rhonda Pacheco to Lead U.S. Operations
Takeda has appointed Rhonda Pacheco, former group vice president of U.S. Cardiometabolic Health at Eli Lilly, as president of its U.S. Business Unit effective September 29, 2025.
ICER Reverses Position on GLP-1 Obesity Drugs, Finds Cost-Effectiveness Despite Budget Concerns
The Institute for Clinical and Economic Review has reversed its 2022 assessment, now finding GLP-1 drugs from Novo Nordisk and Eli Lilly cost-effective for obesity treatment with substantial health benefits beyond weight loss.
Cancer Centers Pioneer Decentralized Clinical Trial Models to Expand Patient Access Nationwide
UNC Lineberger Comprehensive Cancer Center launches hybrid decentralized trials with $250,000 federal funding to serve North Carolina's 33% rural population, reducing travel barriers to Chapel Hill.
insitro and Eli Lilly Partner to Develop AI-Powered ADMET Prediction Models for Small Molecule Drug Discovery
insitro and Eli Lilly announced a collaboration to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.
Eli Lilly Launches TuneLab AI Platform to Democratize Drug Discovery for Biotech Companies
Eli Lilly has launched TuneLab, an AI/ML platform providing biotech companies access to drug discovery models trained on over $1 billion worth of proprietary research data.
Alchemab Therapeutics Initiates Phase 1 Trial of ATLX-1282 and Secures $32 Million Series A Extension
Alchemab Therapeutics has initiated a Phase 1 first-in-human study of ATLX-1282, marking the first clinical candidate from their AI-enabled platform that identifies protective antibodies from disease-resilient individuals.